150 related articles for article (PubMed ID: 9576012)
21. Structural features of the first component of human complement, C1, as revealed by surface iodination.
Villiers CL; Chesne S; Lacroix MB; Arlaud GJ; Colomb MG
Biochem J; 1982 Apr; 203(1):185-91. PubMed ID: 6285892
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of activation of the classical pathway of complement by human neutrophil defensins.
van den Berg RH; Faber-Krol MC; van Wetering S; Hiemstra PS; Daha MR
Blood; 1998 Nov; 92(10):3898-903. PubMed ID: 9808583
[TBL] [Abstract][Full Text] [Related]
23. C1, the first component of complement: structure-function-relationship of C1q and collectins (MBP, SP-A, SP-D, conglutinin), C1-esterases (C1r and C1s), and C1-inhibitor in health and disease.
Loos M; Colomb M
Behring Inst Mitt; 1993 Dec; (93):1-5. PubMed ID: 8172555
[No Abstract] [Full Text] [Related]
24. Binding of purified C1 subcomponents, C1 inactivator and their complexes to immobilized heparin.
McKay EJ; Johnson U; Laurell AB; Mårtensson U; Sjöholm AG
Acta Pathol Microbiol Scand C; 1981 Oct; 89(5):339-44. PubMed ID: 6274149
[TBL] [Abstract][Full Text] [Related]
25. C1 dissociation. Spontaneous generation in human serum of a trimer complex containing C1 inactivator, activated C1r, and zymogen C1s.
Laurell AB; Mårtensson U; Sjöholm AG
J Immunol; 1987 Dec; 139(12):4145-51. PubMed ID: 2826582
[TBL] [Abstract][Full Text] [Related]
26. Trimer and tetramer complexes containing C1 esterase inhibitor, C1r and C1s, in serum and synovial fluid of patients with rheumatic disease.
Laurell AB; Mårtensson U; Sjöholm AG
J Immunol Methods; 1990 May; 129(1):55-61. PubMed ID: 2338498
[TBL] [Abstract][Full Text] [Related]
27. C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion.
Tas SW; Klickstein LB; Barbashov SF; Nicholson-Weller A
J Immunol; 1999 Nov; 163(9):5056-63. PubMed ID: 10528211
[TBL] [Abstract][Full Text] [Related]
28. Leukocyte-derived complement inhibitor. IV. The functional properties of C1 bound to erythrocytes pretreated with leukocyte culture supernatant.
Bernard A; Walter W; Teshima H; Boumsell L; Good RA; Day NK
J Immunol; 1976 Oct; 117(4):1117-26. PubMed ID: 977945
[TBL] [Abstract][Full Text] [Related]
29. Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment.
Hwang HY; Duvall MR; Tomlinson S; Boackle RJ
Mol Immunol; 2008 May; 45(9):2570-80. PubMed ID: 18313756
[TBL] [Abstract][Full Text] [Related]
30. Biosynthesis in vitro of complement subcomponents C1q, C1s and C1 inhibitor by resting and stimulated human monocytes.
Bensa JC; Reboul A; Colomb MG
Biochem J; 1983 Nov; 216(2):385-92. PubMed ID: 6318736
[TBL] [Abstract][Full Text] [Related]
31. Complement activation by immunoglobulin does not depend solely on C1q binding.
Bindon CI; Hale G; Waldmann H
Eur J Immunol; 1990 Feb; 20(2):277-81. PubMed ID: 2311645
[TBL] [Abstract][Full Text] [Related]
32. C1 and human platelets. III. Role of C1 subcomponents in platelet aggregation induced by aggregated IgG.
Wautier JL; Souchon H; Solal LC; Peltier AP; Caen JP
Immunology; 1976 Oct; 31(4):595-9. PubMed ID: 185144
[TBL] [Abstract][Full Text] [Related]
33. Spontaneous activation of the first component of human complement (C1) by an intramolecular autocatalytic mechanism.
Ziccardi RJ
J Immunol; 1982 Jun; 128(6):2500-4. PubMed ID: 6281332
[TBL] [Abstract][Full Text] [Related]
34. Interaction of the envelope glycoprotein of human immunodeficiency virus with C1q and fibronectin under conditions present in human saliva.
Su H; Boackle RJ
Mol Immunol; 1991 Aug; 28(8):811-7. PubMed ID: 1875953
[TBL] [Abstract][Full Text] [Related]
35. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.
Bindon CI; Hale G; Brüggemann M; Waldmann H
J Exp Med; 1988 Jul; 168(1):127-42. PubMed ID: 3260935
[TBL] [Abstract][Full Text] [Related]
36. Activation of C1 by soluble IgG aggregates as detected by a novel one-step hemolytic assay that specifically measures the proenzyme form of C1s.
Doekes G; van Es LA; Daha MR
J Immunol; 1983 Oct; 131(4):1924-9. PubMed ID: 6604753
[TBL] [Abstract][Full Text] [Related]
37. Structure and function of C1 inhibitor.
Davis AE
Behring Inst Mitt; 1989 Jul; (84):142-50. PubMed ID: 2679529
[TBL] [Abstract][Full Text] [Related]
38. Measurement of macromolecular interactions between complement subcomponents C1q, C1r, C1s, and immunoglobulin IgM by sedimentation analysis using the analytical ultracentrifuge.
Poon PH; Schumaker VN
J Biol Chem; 1991 Mar; 266(9):5723-7. PubMed ID: 2005109
[TBL] [Abstract][Full Text] [Related]
39. NH2-terminal calcium-binding domain of human complement C1s- mediates the interaction of C1r- with C1q.
Busby TF; Ingham KC
Biochemistry; 1990 May; 29(19):4613-8. PubMed ID: 2372546
[TBL] [Abstract][Full Text] [Related]
40. Improved method for measuring C1-r-C1-s-(C1 inh)2 complexes by an enzyme-linked immunosorbent assay.
Mathews KP; Herschbach JH; Chambers SL; Zuraw BL
J Clin Lab Anal; 1995; 9(3):196-203. PubMed ID: 7602428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
